Immune Competitors

Summary

IMUNDelisted Stock

USD 0.06 0 4.76%

Analyzing Immune Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Immune Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Immune Therapeutics competition on your existing holdings.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immune Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.

Hype

Prediction

Low	Estimated	High
0.06	0.06	0.06

Details

Intrinsic

Valuation

Low	Real	High
0.06	0.06	0.06

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immune Therapeutics. Your research has to be compared to or analyzed against Immune Therapeutics' peers to derive any actionable benefits. When done correctly, Immune Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Immune Therapeutics.

Immune Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Immune Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Immune and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Immune Therapeutics does not affect the price movement of the other competitor.

	RSPI	BIEI	USRM	NPHC	MYMX
RSPI		0.15	0.43	0.21	0.53	RSPI
BIEI	0.15		0.42	-0.19	0.52	BIEI
USRM	0.43	0.42		0.02	0.8	USRM
NPHC	0.21	-0.19	0.02		0.13	NPHC
MYMX	0.53	0.52	0.8	0.13		MYMX
	RSPI	BIEI	USRM	NPHC	MYMX

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

MYMX	+ 0.8	USRM
MYMX	+ 0.53	RSPI
MYMX	+ 0.52	BIEI
USRM	+ 0.43	RSPI
USRM	+ 0.42	BIEI
NPHC	+ 0.21	RSPI

High negative correlations

NPHC

- 0.19

BIEI

Risk-Adjusted Indicators

There is a big difference between Immune Pink Sheet performing well and Immune Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Immune Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
RSPI	11.15	1.59	0.11	1.54	11.09	(17.01)	30.43	(21.57)	76.50
BIEI	7.30	0.71	0.04	(0.29)	7.30	(15.62)	20.00	(15.38)	65.45
USRM	6.95	(1.03)	0.00	0.43	0.00	0.00	25.00	(33.33)	130.00
NPHC	4.45	1.58	0.00	(1.67)	0.00	0.00	0.00	0.00	150.00
MYMX	3.03	(0.19)	0.00	0.02	0.00	0.00	0.00	0.00	196.15

Immune Therapeutics Competitive Analysis

The better you understand Immune Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Immune Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Immune Therapeutics' competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	IMUN	RSPI	BIEI	USRM	NPHC	MYMX
	4.76 0.06 Immune	0.00 0.01 RespireRx	9.09 0 Premier	0.00 0.0002 USRM	0.00 0.0001 Nutra	0.00 0.01 Mymetics
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Out of control	Very steady	Out of control	Out of control
Market Performance (90 Days Performance)	Very Weak	Very Weak	Modest	Very Weak	Solid	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Dangerous	Dangerous	Dangerous	Dangerous	Above Average	Quite High
Current Valuation (Equity Enterprise Value)	Fairly Valued	Over Valued	Over Valued	Over Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Not Rated	Not Rated	Not Rated	Not Rated	Not Rated	Strong Sell
Current Ratio	0.04 X	0.01 X	0.05 X	N/A	0.03 X	0.01 X
Net Asset	3.14 M	208.74 K	100.94 K	89.84 K	301.79 K	7.63 M
Profit Margin	N/A	N/A	N/A	N/A	28.71 %	N/A
EBITDA	3.8 M	(2.42 M)	20.91 K	(2.61 M)	(365.66 K)	(1.96 M)
Current Valuation	83.25 M	3.18 M	1.6 M	12.15 M	10.33 M	83.16 M
Operating Margin	N/A	N/A	(22.88) %	(19.95) %	(5.58) %	(1.76) %
Retained Earnings	(319.86 M)	(156.09 M)	(3.91 M)	(122.08 M)	N/A	(81.98 M)
Current Asset	22 K	157 K	44.58 K	320 K	N/A	1.38 M
Beta	0.52	0.24	-4.63	-0.69	0.25	0.24
Number Of Employees	15	2	11	15	4	9
Shares Outstanding	82.76 M	119.59 M	999.98 M	634.4 M	7.6 B	303.76 M
Cash Flow From Operations	(231.72 K)	(956.17 K)	(344.18 K)	(1.21 M)	(878.09 K)	(1.7 M)
Total Debt	1.08 M	2.42 M	160.75 K	722.06 K	517.18 K	162 K
Z Score	N/A	N/A	-40.0	N/A	-2.7	-1.4
Return On Asset	-0.45	-8.34	-1.54	-8.45	-1.13	-0.14
Book Value Per Share	(0.03) X	(0.1) X	(0.01) X	(0.02) X	(0) X	(0.21) X
Number Of Shares Shorted	N/A	126	N/A	N/A	N/A	N/A
Current Liabilities	7.49 M	5.05 M	324.55 K	6.96 M	N/A	51.24 M
Total Asset	3.14 M	208.74 K	100.94 K	89.84 K	301.79 K	7.63 M
Debt To Equity	1.97 %	N/A	(1.18) %	(1.03) %	N/A	N/A
Short Ratio	N/A	1.47 X	N/A	N/A	N/A	N/A
Target Price	N/A	0.3	N/A	0.4	0.53	N/A
Shares Owned By Institutions	N/A	N/A	N/A	N/A	0.01 %	N/A
Market Capitalization	39.1 M	837.16 K	4.3 M	3.05 M	759.68 K	5.47 M
Price To Earning	333.33 X	(0.25) X	0.07 X	(1.12) X	N/A	(2.40) X
Price To Sales	161.50 X	1,051 X	112.03 X	30.36 X	6.13 X	12.17 X
Net Income	3.59 M	(3.14 M)	(374.47 K)	(3.84 M)	(769.18 K)	(4.73 M)
Earnings Per Share	0.03 X	(0.04) X	(0.01) X	(0.01) X	N/A	(0.02) X
Shares Owned By Insiders	29.51 %	20.63 %	2.36 %	10.68 %	1.02 %	54.90 %
Revenue	N/A	N/A	14.28 K	3.07 M	51.9 K	3 K
Working Capital	(7.47 M)	(4.89 M)	(279.97 K)	(6.64 M)	N/A	(49.86 M)
Cash And Equivalents	271.53 K	21	71.2 K	10.33 K	10.45 K	350 K
Gross Profit	65.83 K	N/A	1.42 K	148.72 K	8.47 K	(545 K)
Day Typical Price	0.061	0.007	0.0012	2.0E-4	1.0E-4	0.01
Accumulation Distribution	0.0476	N/A	0.23	N/A	N/A	N/A
Market Facilitation Index	0.003	N/A	3.0E-4	N/A	N/A	N/A
Daily Balance Of Power	(1.00)	0.0	0.3333	0.0	0.0	0.0
Period Momentum Indicator	(0)	N/A	1.0E-4	N/A	N/A	N/A
Rate Of Daily Change	0.95	1.0	1.09	1.0	1.0	1.0
Day Median Price	0.0615	0.007	0.0012	2.0E-4	1.0E-4	0.01
Price Action Indicator	(0)	N/A	1.0E-4	N/A	N/A	N/A
Coefficient Of Variation	(3,852)	950.88	1961.19	(1,354)	997.54	29527.27
Mean Deviation	7.16	11.15	7.3	6.95	4.45	3.03
Jensen Alpha	(0.24)	1.59	0.7095	(1.03)	1.58	(0.19)
Total Risk Alpha	(2.14)	(0.39)	(0.87)	(3.45)	(0.44)	(2.17)
Sortino Ratio	N/A	0.1069	0.0394	N/A	N/A	N/A
Downside Variance	N/A	222.23	146.65	N/A	N/A	N/A
Standard Deviation	13.79	16.01	11.12	16.97	15.11	17.21
Kurtosis	5.08	1.89	3.55	9.59	31.34	32.55
Potential Upside	26.86	30.43	20.0	25.0	N/A	N/A
Treynor Ratio	0.2196	1.54	(0.29)	0.4318	(1.67)	0.0163
Maximum Drawdown	68.65	76.5	65.45	130.0	150.0	196.15
Variance	190.13	256.25	123.56	287.91	228.44	296.08
Market Risk Adjusted Performance	0.2296	1.55	(0.28)	0.4418	(1.66)	0.0263
Risk Adjusted Performance	(0.01)	0.0744	0.0408	(0.04)	0.0713	0.0117
Skewness	(0.03)	0.9562	1.27	(1.25)	4.28	0.3352
Semi Deviation	N/A	11.09	7.3	N/A	N/A	N/A
Information Ratio	(0.03)	0.0996	0.043	(0.08)	0.0943	(0)
Value At Risk	(21.11)	(21.57)	(15.38)	(33.33)	N/A	N/A
Expected Short fall	N/A	(17.01)	(15.62)	N/A	N/A	N/A
Downside Deviation	N/A	14.91	12.11	N/A	N/A	N/A
Semi Variance	N/A	122.94	53.29	N/A	N/A	N/A

Immune Therapeutics Competition Performance Charts

Five steps to successful analysis of Immune Therapeutics Competition

Immune Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Immune Therapeutics in relation to its competition. Immune Therapeutics' competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Immune Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Immune Therapeutics' competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Immune Therapeutics, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Immune Therapeutics position

In addition to having Immune Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Online Gaming Thematic Idea Now

Online Gaming

Companies that are involved in the building and marketing of online gaming-related products. The Online Gaming theme has 48 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Online Gaming Theme or any other thematic opportunities.

View All Next

Launch

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Immune Pink Sheet

If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.

	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC